Subscribe To

Price Alert Latest News Economic Calendar News

BETRF / BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California

BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California

VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis and Argel Aguilar-Valles from Carleton University's Department of Neuroscience in Ottawa, Canada, will present on the anti-depressant and anti-anxiety activity of BetterLife's 2-bromo-LSD (“BETR-001”) at the upcoming SOBP Conference, being held April 27-29, 2023 at San Diego, California, USA. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (“LSD”) derivative molecule. Read More

Demo Live Account See Partner Details

Content Topics

Betterlife

Present

Betr

001 Preclinical

Data

2023

Annual

Betr 001

Meeting

Society

Biological

Psychiatry

sobp

Diego

California

Stock

BETRF

Posted: Apr 25 2023, 08:00

Author Name: GlobeNewsWire

BETRF News

By GlobeNewsWire
April 25, 2023

BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California

VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BE

By Proactive Investors
March 29, 2023

BetterLife Pharma says BETR-001 drug candidate featured in Drug Discovery & Development article

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced that an article titled “Non-hallucinogenic LSD derivative reduces depression symptoms in

By Proactive Investors
March 14, 2023

BetterLife Pharma closes $1.5M private placement

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced the closing of a brokered private placement worth $1.5 million. The company is offering

By Proactive Investors
March 9, 2023

Betterlife Pharma's reports positive study findings for lead candidate BETR-001

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) revealed promising findings from a study on its lead candidate BETR-001 (2-bromo-LSD), a non-hallucinoge

By Proactive Investors
March 8, 2023

BetterLife Pharma unveils plans for a private placement offering of units

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) has announced plans for a private placement offering of units, comprising of one common share and one co

By Proactive Investors
January 26, 2023

BetterLife Pharma hires strategic advisory services firm to support development toward clinical trials of its psychedelic compounds

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has engaged Bloom Burton Securities Inc for strategic advisory services to support its

By Proactive Investors
December 7, 2022

BetterLife Pharma closes private placement with help from Negev Capital to fuel clinical programs

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has closed a financing designed to advance its clinical and preclinical studies. The n

By Proactive Investors
December 2, 2022

BetterLife to present BETR-001 preclinical data at the American College of Neuropsychopharmacology meeting in Phoenix

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said that one of its scientific collaborators, Dr Argel Aguilar-Valles from Carleton University's Depart

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.